S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:PBYI

Puma Biotechnology (PBYI) Stock Forecast, Price & News

$2.63
-0.02 (-0.75%)
(As of 09/29/2023 ET)
Compare
Today's Range
$2.60
$2.74
50-Day Range
$2.63
$4.09
52-Week Range
$2.08
$5.16
Volume
105,879 shs
Average Volume
244,376 shs
Market Capitalization
$124.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Puma Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
204.2% Upside
$8.00 Price Target
Short Interest
Bearish
4.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of Puma Biotechnology in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$272,466 Sold Last Quarter
Proj. Earnings Growth
-29.27%
From $0.41 to $0.29 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

785th out of 973 stocks

Pharmaceutical Preparations Industry

375th out of 450 stocks


PBYI stock logo

About Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

PBYI Price History

PBYI Stock News Headlines

Puma Biotechnology (NASDAQ:PBYI) Rating Reiterated by HC Wainwright
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Q2 2023 Puma Biotechnology Inc Earnings Call
H.C. Wainwright Remains a Buy on Puma Biotechnology (PBYI)
Q1 2023 Puma Biotechnology Inc Earnings Call
See More Headlines
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Company Calendar

Last Earnings
8/03/2023
Today
9/29/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PBYI
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+204.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
-0.76%

Debt

Sales & Book Value

Annual Sales
$228 million
Cash Flow
$0.19 per share
Book Value
$0.47 per share

Miscellaneous

Free Float
36,725,000
Market Cap
$124.95 million
Optionable
Optionable
Beta
1.06
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Alan H. AuerbachMr. Alan H. Auerbach (Age 53)
    Founder, Chairman, Pres, CEO & Sec.
    Comp: $1.74M
  • Mr. Maximo F. NouguesMr. Maximo F. Nougues (Age 54)
    CFO & Principal Accounting Officer
    Comp: $781.47k
  • Dr. Alvin F. Wong Pharm.d. (Age 70)
    Chief Scientific Officer
    Comp: $809.69k
  • Mr. Douglas Hunt B.Sc. (Age 58)
    FRAPS, Sr. VP of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law
    Comp: $632.65k
  • Mr. Jeffrey Jerome Ludwig (Age 57)
    Chief Commercial Officer
    Comp: $916.85k
  • Mr. Mariann Ohanesian
    Sr. Director of Investor Relations













PBYI Stock - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings
or view top-rated stocks.

What is Puma Biotechnology's stock price forecast for 2023?

1 Wall Street analysts have issued 12-month price targets for Puma Biotechnology's stock. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 204.2% from the stock's current price.
View analysts price targets for PBYI
or view top-rated stocks among Wall Street analysts.

How have PBYI shares performed in 2023?

Puma Biotechnology's stock was trading at $4.23 on January 1st, 2023. Since then, PBYI shares have decreased by 37.8% and is now trading at $2.63.
View the best growth stocks for 2023 here
.

When is Puma Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PBYI earnings forecast
.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The biopharmaceutical company had revenue of $54.60 million for the quarter, compared to analyst estimates of $51.37 million. Puma Biotechnology had a negative trailing twelve-month return on equity of 10.00% and a negative net margin of 1.09%.

What guidance has Puma Biotechnology issued on next quarter's earnings?

Puma Biotechnology updated its third quarter 2023 earnings guidance on Friday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $54.00 million-$58.00 million, compared to the consensus revenue estimate of $60.49 million.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $2.63.

How much money does Puma Biotechnology make?

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $124.95 million and generates $228 million in revenue each year.

How many employees does Puma Biotechnology have?

The company employs 192 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501.

This page (NASDAQ:PBYI) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -